Gamino v. Thinx Inc., No. EDCV 23-2067 JGB (SHKx), 2024 WL 2429307 (C.D. Cal. Apr. 18, 2024)
Gamino brought a
host of California statutory and common law claims against Thinx, alleging that
Thinx’s period underwear didn’t function as advertised; specifically, that it
was incapable of holding the amount of liquid advertised. The court declined to
dismiss the complaint on a variety of grounds.
Thinx argued that
the absorbency of its products is advertised as performing “up to” a certain
threshold, and that reasonable consumers therefore expect that the products’
performance could be less than the maximum. In addition, it argued that no
reasonable consumer would read the phrase “prevents leaks” as guaranteeing the
products will “absorb whatever amount of fluid is dispensed into them.”
The court disagreed:
The basis of Plaintiff’s claims is not that Defendant’s products
occasionally perform below the maximum absorbency advertised, but that the
products “do not hold” and “cannot absorb” the “claimed amounts of fluid, and
instead leak.” … Plaintiff alleges that Defendant represents its products’
absorbency using specific fluid amounts on its website, product pages, and
packaging. … Plaintiff also alleges that testing reveals representative Thinx
products cannot absorb the amount advertised on Thinx’s packaging and website,
but that each of the products leaks. … Finally, Plaintiff alleges that other
consumers of Thinx products have experienced leakage “with even the smallest
amount[t] of blood” or “in less than 15 minutes.” … Based on Plaintiff’s
allegations, a reasonable consumer could be misled into believing Defendant’s
products can fulfill their advertised, maximum absorbency.
The court quoted
prior caselaw: “[M]ultiple courts have found that ‘up to’ representations may
materially mislead reasonable consumers.” The allegation that Thinx’s products
lacked the capacity to absorb the advertised amounts, plus the lack of
allegations that Thinx listed customer-specific factors which could reduce performance
(beyond the broad statement that “individual results may vary”), meant that “up
to” was no help.
Thinx also argued
that Gamino did not suffer an economic injury because she could have received a
refund for her purchase. That conflated injury with remedy—despite available
refunds, she suffered an economic injury “as soon as she relie[d] on a
defendant’s deceptive advertising and part[ed] with more money than she
otherwise would have paid.”
Also, Gamino plausibly
alleged lack of absorption with allegations of (1) her own experience, (2) the
experiences of other consumers, and (3) testing “by using cough syrup to mimic
the viscosity of menstrual flow, just as some manufacturers do to test pads and
tampons.” At this stage, she didn’t need to allege “which products were tested,
who did the testing, whether Thinx uses the same method to test its products,”
or “how much the products absorbed when she wore them.”
Gamino also had
standing to seek equitable remedies because she plausibly pled that she was
still interested in period underwear and wanted to purchase it if she could rely
on the advertising. “While the Court likely cannot order Defendant to
manufacture a wholly new product ... it surely can issue some form of
injunctive relief that would redress Plaintiff’s injury.”
Finally, the court
declined to wait for the FDA under the primary jurisdiction doctrine. Among other
things, “there is no concrete evidence that the FDA is currently involved in
creating a new regulation about how to test the absorbency of period
underwear.” Courts “have generally declined to dismiss the complaint on primary
jurisdiction absent concrete evidence that the FDA is currently involved in
creating a new regulation concerning the subject of the lawsuit.”
No comments:
Post a Comment